300 results found.

Extraocular Retinoblastoma Clinical Trial using autologous bone marrow transplantation; autologous hematopoietic stem cell transplantation; in vitro-treated peripheral blood stem cell transplantation; cisplatin; cyclophosphamide; etoposide; filgrastim; carboplatin; vincristine sulfate; thiotepa; radiation therapy

Children's Oncology Group - Recruiting N/A to 10 years.
- A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma.
autologous bone marrow transplantation; autologous hematopoietic stem cell transplantation; in vitro-treated peripheral blood stem cell transplantation; cisplatin; cyclophosphamide; etoposide; filgrastim; carboplatin; vincristine sulfate; thiotepa; radiation therapy

Candidiasis Clinical Trial using micafungin; amphotericin B deoxycholate

Astellas Pharma Inc - Recruiting N/A to 120 Days.
- A Phase 3, Randomized, Double-Blind, Multi-Center Study to Compare the Efficacy and Safety of Micafungin Versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis.
micafungin; amphotericin B deoxycholate

Leukodystrophy, Metachromatic, Hereditary Central Nervous System Clinical Trial using Natural History Study of Children With Metachromatic Leukodystrophy

Shire - Recruiting N/A to 12 years.
- Natural History Study of Children With Metachromatic Leukodystrophy.
Natural History Study of Children With Metachromatic Leukodystrophy

Hypofibrinogenemia, Congenital, or Afibrinogenemia, Congenital Clinical Trial using biological: human fibrinogen concentrate

Laboratoire français de Fractionnement et de Biotechnologies - Recruiting N/A to 12 years.
- Clinical Pharmacology, Efficacy and Safety Study of FGTW in Paediatric Patients With Severe Congenital Fibrinogen Deficiency.
biological: human fibrinogen concentrate

Infant, Premature, Bronchopulmonary Dysplasia, or Asthma Clinical Trial

Indiana University - Recruiting 2 Months to 24 Months.
- Growth of Airways and Lung Parenchyma.

Adult Primary Hepatocellular Carcinoma, Localized Unresectable Ad Clinical Trial using sorafenib tosylate; placebo; doxorubicin hydrochloride; doxorubicin-eluting beads; cisplatin; mitomycin C

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase III Randomized, Double-Blind Trial of Chemoembolization With or Without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients With and Without Vascular Invasion.
sorafenib tosylate; placebo; doxorubicin hydrochloride; doxorubicin-eluting beads; cisplatin; mitomycin C

Tourette Disorder, or Tourette Syndrome Clinical Trial using placebo; extended-release guanfacine (Intuniv)

Yale University - Recruiting 6 years to 17 years.
- Guanfacine in Children With Tic Disorders: A Multi-site Study.
placebo; extended-release guanfacine (Intuniv)

Influenza A Clinical Trial using Anti-Influenza Plasma; Standard Care

National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting N/A or older.
- A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza A Immune Plasma for the Treatment of Influenza A (IRC002).
Anti-Influenza Plasma; Standard Care

Chemotherapy-induced Nausea and Vomiting Clinical Trial using Fosaprepitant 150 mg; Fosaprepitant 60 mg; Fosaprepitant 20 mg; Placebo Fosaprepitant; Ondansetron

Merck Sharp & Dohme Corp. - Recruiting N/A to 17 years.
- A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Emetogenic Chemotherapy.
Fosaprepitant 150 mg; Fosaprepitant 60 mg; Fosaprepitant 20 mg; Placebo Fosaprepitant; Ondansetron

Rhinitis, Allergic, Perennial, or Rhinitis, Allergic, Nonseasonal Clinical Trial using MK-8237 tablets; Placebo tablets; Rescue Medication: Self-Injectable Epinephrine; Rescue Medication: Loratadine tablets; Rescue Medication: Olopatadine ophthalmic drops; Rescue Medication: Mometasone furoate nasal spray

Merck Sharp & Dohme Corp. - Recruiting 12 years or older.
- A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001-00).
MK-8237 tablets; Placebo tablets; Rescue Medication: Self-Injectable Epinephrine; Rescue Medication: Loratadine tablets; Rescue Medication: Olopatadine ophthalmic drops; Rescue Medication: Mometasone furoate nasal spray

Venous Thrombosis Clinical Trial using Rivaroxaban (Xarelto, BAY59-7939); Standard of care

Bayer - Recruiting 6 years to 17 years.
- 30-day, Open-label, Active-controlled, Randomized Study of the Safety, Efficacy and the Pharmacokinetic and Pharmacodynamic Properties of Oral Rivaroxaban in Children With Various Manifestations of Venous Thrombosis.
Rivaroxaban (Xarelto, BAY59-7939); Standard of care

Diabetes Mellitus, Type 2 Clinical Trial using Canagliflozin 100 mg; Canagliflozin 50 mg; Canagliflozin 300 mg; Placebo

Janssen Research & Development, LLC - Recruiting 10 years to 17 years.
- Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ò10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin.
Canagliflozin 100 mg; Canagliflozin 50 mg; Canagliflozin 300 mg; Placebo

Candidemia Clinical Trial using anidulafungin; fluconazole

Pfizer - Recruiting 1 Month to 17 years.
- A Prospective, Open-Label Study To Assess The Pharmacokinetics, Safety & Efficacy Of Anidulafungin When Used To Treat Children With Invasive Candidiasis, Including Candidaemia.
anidulafungin; fluconazole

Brain and Central Nervous System Tumors, Cognitive/Functional Eff Clinical Trial using modafinil; placebo

University of South Florida - Recruiting 6 years to 17 years.
- A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor.
modafinil; placebo

Post-Operative Nausea, or Post-Operative Vomiting Clinical Trial using Aprepitant; Placebo to match aprepitant; Ondansetron; Placebo to match ondansetron

Merck Sharp & Dohme Corp. - Recruiting N/A to 17 years.
- A Phase IIb, Partially-Blinded, Randomized, Active Comparator- Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Aprepitant in Pediatric Patients for the Prevention of Post Operative Nausea and Vomiting.
Aprepitant; Placebo to match aprepitant; Ondansetron; Placebo to match ondansetron

Diffuse Intrinsic Pontine Glioma Clinical Trial using Bevacizumab; Erlotinib; Temozolomide; Irradiation

Dana-Farber Cancer Institute - Recruiting 3 years to 18 years.
- Phase II Trial of Molecularly Determined Treatment of Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas.
Bevacizumab; Erlotinib; Temozolomide; Irradiation

Hereditary Angioedema Clinical Trial using icatibant

Shire Development LLC - Recruiting 2 years to 17 years.
- A Multicenter, Open-Label, Non-Randomized Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Single Subcutaneous Administration of Icatibant in Children and Adolescents With Hereditary Angioedema.
icatibant

Pharmacokinetics, Cardiopulmonary Bypass, or Children Clinical Trial

Duke University - Recruiting N/A to 2 years.
- Pharmacokinetics of Dexmedetomidine in Children During Cardiopulmonary Bypass (CPB).

Polyarticular-course Juvenile Idiopathic Arthritis (JIA) Clinical Trial using Certolizumab Pegol (CZP)

UCB, Inc. - Recruiting 2 years to 17 years.
- A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA).
Certolizumab Pegol (CZP)

Metachromatic Leukodystrophy Clinical Trial using Recombinant human arylsulfatase A

Shire Development LLC - Recruiting N/A to 12 years.
- A Phase I/II Multicenter Open-label Dose Escalation Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy.
Recombinant human arylsulfatase A

Pediatric Cancer Clinical Trial using Education; Cotinine Education

University of South Florida - Recruiting 2 years to 12 years.
- Cotinine Feedback as an Intervention to Change Parental/Caregiver Smoking Behavior Around Children With Cancer.
Education; Cotinine Education

Long QT Syndrome Clinical Trial

Pediatrix Medical Group - Recruiting N/A to 20 years.
- Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome.

Prevention Harmful Effects Clinical Trial using Healthy Sleep intervention; Healthy Nutrition intervention

Tel Aviv University - Recruiting 3 years to 6 years.
- Sleep, Nutrition and Psychological Functioning in Kindergarten Children: A Longitudinal Intervention Study.
Healthy Sleep intervention; Healthy Nutrition intervention

Clostridium Difficile Colitis Clinical Trial using FMT; placebo

MemorialCare Health System - Recruiting 1 year to 21 years.
- A Randomized, Placebo-controlled Pilot Trial to Administer Fecal Microbial Therapy (Stool Transplant) or Placebo in Children Ages 8 to 18 With Recurrent C. Difficile Infection.
FMT; placebo

Pulmonary Alveolar Proteinosis (PAP) Clinical Trial using MRI; Research CT if clinical one is complete before the pre lavage

Children's Hospital Medical Center, Cincinnati - Recruiting 8 years to 75 years.
- Investigator Initiated Trial.
MRI; Research CT if clinical one is complete before the pre lavage

Fabry Disease Clinical Trial using agalsidase alfa

Shire Development LLC - Recruiting N/A or older.
- A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagalr (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease.
agalsidase alfa

HIV Infections Clinical Trial using Current ARV medications; Current TB medications; Current hormonal contraceptive medications

National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting N/A or older.
- Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum.
Current ARV medications; Current TB medications; Current hormonal contraceptive medications

Hematological Malignancies, Certain Lysosomal Storage and Peroxis Clinical Trial using A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)

Center for International Blood and Marrow Transplant Research - Recruiting N/A or older.
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications.
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)

Mucopolysaccharidosis II, MPS II, or Hunter Syndrome Clinical Trial

Shire Development LLC - Recruiting 2 years to 18 years.
- A Prospective, Longitudinal, Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II).

Venous Thromboembolism Clinical Trial using dabigatran etexilate; standard of care

Boehringer Ingelheim - Recruiting N/A to 17 years.
- Open-label, Randomized, Parallel-group, Active-controlled, Multi-centre Non-inferiority Study of Dabigatran Etexilate Versus Standard of Care for Venous Thromboembolism Treatment in Children From Birth to Less Than 18 Years of Age.
dabigatran etexilate; standard of care

Asthma Clinical Trial using Tiotropium low dose QD; Tiotropium high dose QD; Placebo

Boehringer Ingelheim - Recruiting 6 years to 11 years.
- A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (2.5 mcg and 5 mcg) Delivered Via Respimatr Inhaler Once Daily in the Evening Over 48 Weeks in Children (6 to 11 Years Old) With Moderate Persistent Asthma.
Tiotropium low dose QD; Tiotropium high dose QD; Placebo

Childhood Mixed Glioma, Untreated Childhood Anaplastic Astrocytom Clinical Trial using veliparib; temozolomide; 3-dimensional conformal radiation therapy; intensity-modulated radiation therapy; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting N/A to 21 years.
- A Phase I/II Study of ABT-888, an Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG).
veliparib; temozolomide; 3-dimensional conformal radiation therapy; intensity-modulated radiation therapy; pharmacological study; laboratory biomarker analysis

Venous Thromboembolism Clinical Trial using dabigatran etexilate

Boehringer Ingelheim - Recruiting 1 year to 11 years.
- Single Dose Open-label PK/PD, Safety and Tolerability Study of Dabigatran Etexilate Mesilate Given at the End of Standard Anticoagulant Therapy in Successive Groups of Children Aged 2 Years to Less Than 12 Years Followed by 1 Year to Less Than 2 Years.
dabigatran etexilate

Diabetes Mellitus, Type 2 Clinical Trial using placebo; BI1356 low dose; BI1356 high dose

Boehringer Ingelheim - Recruiting 10 years to 17 years.
- A Randomised, Double-blind, Placebo-controlled, Parallel Group Dose-finding Study of Linagliptin (1 and 5 mg Administered Orally Once Daily) Over 12 Weeks in Children and Adolescents, From 10 to 17 Years of Age, With Type 2 Diabetes Mellitus.
placebo; BI1356 low dose; BI1356 high dose

B-cell Childhood Acute Lymphoblastic Leukemia, Peripheral T-cell Clinical Trial using dexamethasone; mitoxantrone hydrochloride; temsirolimus; vincristine sulfate; pegaspargase; methotrexate; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 1 year to 21 years.
- A Phase 1 Study of Temsirolimus in Combination With Intensive Re-Induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma.
dexamethasone; mitoxantrone hydrochloride; temsirolimus; vincristine sulfate; pegaspargase; methotrexate; laboratory biomarker analysis; pharmacological study

Hereditary Angioedema Clinical Trial using CINRYZE

ViroPharma - Recruiting 6 years to 11 years.
- A Phase 3, Multicenter, Randomized, Single-Blind, Dose-Ranging, Crossover Study to Evaluate the Safety and Efficacy of Intravenous Administration of CINRYZEr (C1 Esterase Inhibitor [Human]) for the Prevention of Angioedema Attacks in Children 6 to 11 Years of Age With Hereditary Angioedema.
CINRYZE

Asthma Clinical Trial using Placebo; Tiotropium low dose mcg; Tiotropium high dose

Boehringer Ingelheim - Recruiting 6 years to 11 years.
- A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (2.5 mcg and 5 mcg) Delivered Via Respimat® Inhaler Once Daily in the Evening Over 12 Weeks as add-on Controller Therapy on Top of Usual Care in Children (6 to 11 Years Old) With Severe Persistent Asthma.
Placebo; Tiotropium low dose mcg; Tiotropium high dose

HIV Infections Clinical Trial using Dolutegravir (DTG) tablet formulation; DTG oral pediatric granules taken as suspension or granules

National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting N/A to 17 years.
- Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of GSK1349572, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents.
Dolutegravir (DTG) tablet formulation; DTG oral pediatric granules taken as suspension or granules

Hematologic Malignancies, Disorder Related to Transplantation, or Clinical Trial using Preparative Regimen

St. Jude Children's Research Hospital - Recruiting N/A to 21 years.
- Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen.
Preparative Regimen

Colic Clinical Trial using Biogaia L. reuteri DSM 17938; Probiotic Placebo

The Hospital for Sick Children - Recruiting N/A to 180 Days.
- Lactobacillus Reuteri DSM 17938 Versus Placebo in the Treatment of Infantile Colic: A Randomized Double-blind Controlled Trial.
Biogaia L. reuteri DSM 17938; Probiotic Placebo

Autism Spectrum Disorders Clinical Trial using Vasopressin; Placebo

Stanford University - Recruiting 6 years to 12 years.
- Randomized Placebo-controlled Trial of Vasopressin Treatment for Social Deficits in Children With Autism.
Vasopressin; Placebo

Migraine, Migraine Disorders, or Headache Clinical Trial using Amitriptyline; Topiramate; Placebo

Children's Hospital Medical Center, Cincinnati - Recruiting 8 years to 17 years.
- Amitriptyline and Topiramate in the Prevention of Childhood Migraine.
Amitriptyline; Topiramate; Placebo

Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood A Clinical Trial using WEE1 inhibitor MK-1775; radiation therapy; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 37 Months to 21 years.
- A Phase 1 Study of MK-1775 Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas.
WEE1 inhibitor MK-1775; radiation therapy; pharmacological study; laboratory biomarker analysis

Autism Spectrum Disorders Clinical Trial

Children's Hospital Medical Center, Cincinnati - Recruiting 3 years to 25 years.
- Extracellular Signal-Related Kinase Biomarker Development in Autism.

Autistic Disorder Clinical Trial using Acamprosate; Placebo

Children's Hospital Medical Center, Cincinnati - Recruiting 5 years to 17 years.
- Double-Blind Placebo-Controlled Study of Acamprosate in Autism.
Acamprosate; Placebo

Recurrent Neuroblastoma Clinical Trial using temozolomide; irinotecan hydrochloride; temsirolimus; monoclonal antibody Ch14.18; sargramostim; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting N/A or older.
- A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408) in Children With Refractory, Relapsed or Progressive Neuroblastoma.
temozolomide; irinotecan hydrochloride; temsirolimus; monoclonal antibody Ch14.18; sargramostim; laboratory biomarker analysis

Childhood Infections Clinical Trial

Helmholtz Centre for Infection Research - Recruiting 1 year to 3 years.
- The Investigation of Methods to Capture Acute Respiratory and Gastrointestinal Infections of Children Aged 1 to 3 Years. Feasibility Study for the Braunschweig Birth Cohort L”wenKIDS (Infections and the Development of the Immune System).

Venous Thromboembolism Clinical Trial using dabigatran etexilate

Boehringer Ingelheim - Recruiting 1 year to 2 years.
- Single Dose Open-label PK/PD, Safety and Tolerability Study of Dabigatran Etexilate Mesilate Given at the End of Standard Anticoagulant Therapy in Children Aged 1 Year to Less Than 2 Years in Conjunction With Study 1160.89.
dabigatran etexilate

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Burkitt Lym Clinical Trial using CPX-351

Children's Hospital Medical Center, Cincinnati - Recruiting 12 Months to 30 years.
- A Phase I/Pilot Study of CPX-351 for Children, Adolescents and Young Adults With Recurrent or Refractory Hematologic Malignancies.
CPX-351

Gastroenteritis Clinical Trial using Saccharomyces boulardii; Probiotics combination; Placebo

Sinaloa Pediatric Hospital - Recruiting 1 Month to 5 years.
- Efficacy of Two Probiotic Preparations in Children With Acute Viral Diarrhoea, Randomised Controlled Trial.
Saccharomyces boulardii; Probiotics combination; Placebo

Fragile X Syndrome Clinical Trial using acamprosate; Placebo

Children's Hospital Medical Center, Cincinnati - Recruiting 5 years to 23 years.
- Double-Blind, Placebo-Controlled Proof of Concept Study in Youth With Fragile X Syndrome.
acamprosate; Placebo

Traumatic Brain Injury, TBI, or ADHD Clinical Trial using Methylphenidate; Placebo

Children's Hospital Medical Center, Cincinnati - Recruiting 6 years to 17 years.
- Efficacy of Methylphenidate for Management of Long-Term Attention Problems After Pediatric Traumatic Brain Injury (TBI).
Methylphenidate; Placebo

Incontinence Associated Dermatitits Clinical Trial using Skin care regimen with Calmoseptine ointment; Skin care regimen with Destin ointment

University of the Philippines - Recruiting 12 years or older.
- A Randomized Controlled Clinical Study Comparing the Efficacy and Safety of Calmoseptine vs Destin Maximum Strenght Diaper Rash Paste in Treatment of Incontinence Associated Dermatitis in Older Children and Adults.
Skin care regimen with Calmoseptine ointment; Skin care regimen with Destin ointment

Autism Spectrum Disorders Clinical Trial using Riluzole; placebo

Children's Hospital Medical Center, Cincinnati - Recruiting 12 years to 26 years.
- A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders.
Riluzole; placebo

Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineobla Clinical Trial using temozolomide; irinotecan hydrochloride; bevacizumab

National Cancer Institute (NCI) - Recruiting N/A to 21 years.
- Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, a COG Randomized Phase II Screening Trial.
temozolomide; irinotecan hydrochloride; bevacizumab

Stage IB Breast Cancer, or Stage II Breast Cancer Clinical Trial using regional nodal XRT; chestwall XRT; WBI

National Surgical Adjuvant Breast and Bowel Project (NSABP) - Recruiting 18 years or older.
- A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy.
regional nodal XRT; chestwall XRT; WBI

Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, or Clinical Trial using cabozantinib-s-malate; sunitinib malate; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Randomized Phase II Study Comparing Cabozantinib With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma.
cabozantinib-s-malate; sunitinib malate; laboratory biomarker analysis

Tuberculosis, or HIV Infections Clinical Trial using Rifapentine (RPT); Isoniazid (INH); Pyridoxine (Vitamin B6)

National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting 13 years or older.
- Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection.
Rifapentine (RPT); Isoniazid (INH); Pyridoxine (Vitamin B6)

Suicide, Depression, or Family Relationships Clinical Trial using Attachment-Based Family Therapy; Family-Enhanced Non-directive Supportive Therapy

Drexel University - Recruiting 12 years to 18 years.
- Attachment Based Family Therapy (ABFT) for Suicidal Adolescents.
Attachment-Based Family Therapy; Family-Enhanced Non-directive Supportive Therapy

Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Clinical Trial using Teplizumab

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - Recruiting 8 years to 45 years.
- AntiCD3 Mab (Teplizumab) For Prevention of Diabetes In Relatives At-Risk for Type 1 Diabetes Mellitus.
Teplizumab

Human Immunodeficiency Virus (HIV) Clinical Trial using Maraviroc

ViiV Healthcare - Recruiting 2 years to 18 years.
- An Open-Label, Multicenter, Multiple-Dose Pharmacokinetic, Safety And Efficacy Trial Of Maraviroc In Combination With Optimized Background Therapy For The Treatment Of Antiretroviral-Experienced CCR5-Tropic HIV-1 Infected Children 2 - <18 Years Of Age.
Maraviroc

Asthma Clinical Trial using Standard nebulizer; PARI LC Sprint Sp nebulizer

Centre Hospitalier Universitaire de NÄ«mes - Recruiting 6 Months to 36 Months.
- Efficacy of the PARI LC Sprint Sp Nebulizer for Acute Asthma Attack in Hospitalized Children Less Than 36 Months of Age.
Standard nebulizer; PARI LC Sprint Sp nebulizer

Natural Pregnancy, or Pregnancy, Ovarian Clinical Trial

Assistance Publique - Hôpitaux de Paris - Recruiting 26 years to 40 years.
- Assessment of the Risk of Imprinting Defects in Children Born Following Assisted Reproductive Technologies (ART).

Infections Clinical Trial

Duke University - Recruiting N/A to 18 years.
- CSF Pharmacokinetics of Antimicrobials in Children.

Juvenile Myelomonocytic Leukemia Clinical Trial using Stem Cell Transplant

Masonic Cancer Center, University of Minnesota - Recruiting N/A to 18 years.
- Hematopoietic Cell Transplantation in Children With Juvenile Myelomonocytic Leukemia.
Stem Cell Transplant

Neuroblastoma Recurrent Clinical Trial using Dasatinib; Rapamycin; Irinotecan; Temozolomide

University of Regensburg - Recruiting N/A to 25 years.
- Prospective, Open Label, Randomized Phase II Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-risk Neuroblastoma.
Dasatinib; Rapamycin; Irinotecan; Temozolomide

Osteonecrosis, Acute Lymphoblastic Leukaemia, or Lymphoblastic Ly Clinical Trial

Heinrich-Heine University, Duesseldorf - Recruiting 10 years to 18 years.
- Part I: Incidence, Clinical Course and Significance of MRI for Early Diagnosis of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Part II: Susceptibility for Aseptic Osteonecroses in Children and Adolescents With Chemotherapy for ALL or LBL.

Mechanical Ventilation for More Than 48 Hours Clinical Trial using 0.12% chlorhexidine solution; Placebo

Sinaloa Pediatric Hospital - Recruiting 1 Month to 18 years.
- Chlorhexidine Gluconate for Prevention of Ventilator Associated Pneumonia in a Pediatric Intensive Care Unit..
0.12% chlorhexidine solution; Placebo

Pain Clinical Trial using gabapentin; Tramadol; Ibuprofen

Children's Hospitals and Clinics of Minnesota - Recruiting 4 years to 15 years.
- A Comparison of Postoperative Tramadol/Gabapentin/Acetaminophen Versus Tramadol/Placebo/Acetaminophen in Children Undergoing Tonsillectomy.
gabapentin; Tramadol; Ibuprofen

Paediatric Antimicrobial Pharmacokinetics Clinical Trial

St George's, University of London - Recruiting N/A to 15 years.
- Neonatal and Paediatric Pharmacokinetics of Antimicrobials Study.

Breast Cancer Clinical Trial using doxorubicin hydrochloride; enalapril maleate

Masonic Cancer Center, University of Minnesota - Recruiting 18 years or older.
- The Effect of Enalapril on Doxorubicin Exposure in Adjuvant Breast Cancer Treatment.
doxorubicin hydrochloride; enalapril maleate

Pharyngitis, or Tonsillitis Clinical Trial using Azithromycin

Pfizer - Recruiting 12 years to 17 years.
- Ocular Effects Of Azithromycin Oral Solution In Pediatric Patients With Pharyngitis/Tonsillitis.
Azithromycin

Respiratory Tract Infection, Bronchitis, Bronchiolitis, or Pneumo Clinical Trial using xTAG RVP v3

Luminex Molecular Diagnostics - Recruiting N/A or older.
- A Two Arm, Multi-Centre Clinical Evaluation of the xTAG Respiratory Viral Panel v3 Test in Patients With Clinical Signs and Symptoms of Respiratory Tract Infection.
xTAG RVP v3

Relapsed B-Cell Acute Lymphoblastic Leukemia Clinical Trial using leukapheresis or collection of PBMCs; cyclophosphamide; modified T cells

Memorial Sloan-Kettering Cancer Center - Recruiting N/A to 26 years.
- A Phase I Trial of Autologous T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia.
leukapheresis or collection of PBMCs; cyclophosphamide; modified T cells

Hemophilia A Clinical Trial using Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method

Baxter Healthcare Corporation - Recruiting N/A or older.
- ADVATE Hemophilia A Outcome Database.
Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method

Hypoglycemia Clinical Trial using G-Pen Mini™ (glucagon injection)

Xeris Pharmaceuticals - Recruiting 18 years to 30 years.
- A Randomized, Phase 2a, Blinded, 3-Way Crossover Dose-Ranging Study With G-Pen Mini™ (Glucagon Injection) to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Type 1 Diabetes Mellitus (T1DM).
G-Pen Mini™ (glucagon injection)

Ewing Family of Tumors, Rhabdomyosarcoma Clinical Trial using Lipegfilgrastim

Teva Pharmaceutical Industries - Recruiting 2 years to 17 years.
- Multicenter, Open-label Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD), Efficacy, Safety, Tolerability, and Immunogenicity of a Single, Subcutaneous Dose of 100æg/kg XM22 in 21 Children With Ewing Family of Tumors or Rhabdomyosarcoma.
Lipegfilgrastim

Biliary Atresia Clinical Trial

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - Recruiting 1 year to 75 years.
- Biliary Atresia Study in Infants and Children (BASIC).

Respiratory Syncytial Virus Infections Clinical Trial

AbbVie - Recruiting N/A to 24 Months.
- Documentation of Safety and Efficacy of Synagis in Preterm Infants.

Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Ca Clinical Trial using cisplatin; paclitaxel; carboplatin; brachytherapy

Gynecologic Oncology Group - Recruiting 18 years or older.
- A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma.
cisplatin; paclitaxel; carboplatin; brachytherapy

Pneumococcal Infection Clinical Trial using Prevnar 13 (PVC13)

National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting 55 years to 74 years.
- A Phase IIb, Open-Label, Dose-Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine.
Prevnar 13 (PVC13)

Staphylococcal Infection Clinical Trial using Trimethoprim-sulfamethoxazole (TS); Placebo; Clindamycin

National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting 6 Months to 85 years.
- Randomized, Double-Blind Trial of Clindamycin, Trimethoprim-Sulfamethoxazole, or Placebo for Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus.
Trimethoprim-sulfamethoxazole (TS); Placebo; Clindamycin

Clubfoot Clinical Trial

University of British Columbia - Recruiting 18 Months to 5 years.
- Pedobarographic Assessments of Clubfoot Treated Patients.

Breast Cancer Clinical Trial using Capecitabine; Exemestane; Everolimus

Novartis - Recruiting 18 years or older.
- Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in the Treatment of Postmenopausal Women With ER+Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Prior Letrozole or Anastrozole..
Capecitabine; Exemestane; Everolimus

Ovarian Carcinosarcoma, Recurrent Ovarian Epithelial Cancer, Recu Clinical Trial using paclitaxel; carboplatin; ifosfamide

Gynecologic Oncology Group - Recruiting 18 years or older.
- A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary.
paclitaxel; carboplatin; ifosfamide

Childhood Central Nervous System Choriocarcinoma, Childhood Centr Clinical Trial using therapeutic conventional surgery; 3-dimensional conformal radiation therapy; intensity-modulated radiation therapy; carboplatin; etoposide; ifosfamide

Children's Oncology Group - Recruiting 3 years to 21 years.
- Phase 2 Trial of Response-Based Radiation Therapy for Patients With Localized Central Nervous System Germ Cell Tumors (CNS GCT).
therapeutic conventional surgery; 3-dimensional conformal radiation therapy; intensity-modulated radiation therapy; carboplatin; etoposide; ifosfamide

Medulloblastoma Clinical Trial using Craniospinal Irradiation with boost to the primary tumor site; Cyclophosphamide; Cisplatin; Vincristine; Vismodegib; Pemetrexed; Gemcitabine; Aerobic Training; Neurocognitive Remediation

St. Jude Children's Research Hospital - Recruiting 3 years to 21 years.
- A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma.
Craniospinal Irradiation with boost to the primary tumor site; Cyclophosphamide; Cisplatin; Vincristine; Vismodegib; Pemetrexed; Gemcitabine; Aerobic Training; Neurocognitive Remediation

HIV, Acquired Immunodeficiency Syndrome, or Cardiovascular Diseas Clinical Trial using Exercise Program; Control Group

University of Miami - Recruiting N/A to 25 years.
- Atherosclerotic Risk and Response to Exercise Intervention in HIV+ Children.
Exercise Program; Control Group

Sleep Disorders Clinical Trial using Circadin 2/5/10 mg; Placebo

Neurim Pharmaceuticals Ltd. - Recruiting 2 years to 17 years.
- A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadinr to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities.
Circadin 2/5/10 mg; Placebo

Severe Dehydration Clinical Trial using Serial Weights; IVC/Aorta Ultrasound; Clinical Assessment

Rhode Island Hospital - Recruiting N/A to 60 Months.
- Assessment of Severe Dehydration in Children With Diarrhea in Bangladesh.
Serial Weights; IVC/Aorta Ultrasound; Clinical Assessment

Acute Otitis Media Clinical Trial using AR01; Glycerin ear drops

Arbor Pharmaceuticals, Inc. - Recruiting 2 Months to 18 years.
- A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years.
AR01; Glycerin ear drops

Juvenile Idiopathic Arthritis Clinical Trial

Bristol-Myers Squibb - Recruiting N/A to 17 years.
- An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis.

Retinitis Pigmentosa, or Inherited Ophthalmic Diseases Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- National Ophthalmic Genotyping and Phenotyping Network, Stage 1 - Creation of DNA Repository for Inherited Ophthalmic Diseases.

Cancer Survivor Clinical Trial using carvedilol; placebo; pharmacogenomic studies; laboratory biomarker analysis; quality-of-life assessment; polymorphism analysis; microarray analysis; polymerase chain reaction; enzyme-linked immunosorbent assay; questionnaire administration

City of Hope Medical Center - Recruiting 16 years or older.
- Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Congestive Heart Failure (PREVENT-CHF): A Phase IIB Randomized Placebo-Controlled Trial.
carvedilol; placebo; pharmacogenomic studies; laboratory biomarker analysis; quality-of-life assessment; polymorphism analysis; microarray analysis; polymerase chain reaction; enzyme-linked immunosorbent assay; questionnaire administration

Brain Disorders, Birth Defects, or Craniofacial Differences Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 80 years.
- Study on Moebius Syndrome and Other Congenital Facial Weakness Disorders.

Spinal Muscular Atrophy (SMA) Clinical Trial

Ohio State University - Recruiting N/A to 6 Months.
- Spinal Muscular Atrophy (SMA) Biomarkers in the Immediate Postnatal Period of Development.

Acute Otitis Media Clinical Trial using AR01; Glycerin ear drops

Arbor Pharmaceuticals, Inc. - Recruiting 2 Months to 18 years.
- A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years.
AR01; Glycerin ear drops

Major Depressive Disorder Clinical Trial using desvenlafaxine succinate sustained release; fluoxetine; placebo

Pfizer - Recruiting 7 years to 17 years.
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Fluoxetine-Referenced, Parallel-Group Study To Evaluate The Safety, Efficacy, And Tolerability Of DVS SR In Children And Adolescent Outpatients With Major Depressive Disorder.
desvenlafaxine succinate sustained release; fluoxetine; placebo

Major Depressive Disorder Clinical Trial using DVS SR

Pfizer - Recruiting 7 years to 18 years.
- A 6-Month, Open-Label, Multi-Center, Flexible-Dose Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of Desvenlafaxine Succinate Sustained-Release (DVS SR) Tablets in the Treatment of Children and Adolescent Outpatients With Major Depressive Disorder.
DVS SR

Primary Hemophagocytic Lymphohistiocytosis Clinical Trial using NI-0501

NovImmune SA - Recruiting N/A to 18 years.
- A Pilot, Open-label, Single Arm, Multicentre Study to Explore Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (Anti-IFN?) Monoclonal Antibody, in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis Which Has Reactivated..
NI-0501

Acute Myeloid Leukemia (AML), or Myelodysplastic Syndrome (MDS) Clinical Trial using Treosulfan

Center for International Blood and Marrow Transplant Research - Recruiting N/A to 21 years.
- A Phase II Study of Treosulfan/Fludarabine/Low Dose Total Body Irradiation as a Preparative Regimen for Children With AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation.
Treosulfan

Major Depressive Disorder Clinical Trial using Desvenlafaxine Succinate Sustained-Release; Placebo

Pfizer - Recruiting 7 years to 17 years.
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate the Efficacy, Safety And Tolerability Of Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder.
Desvenlafaxine Succinate Sustained-Release; Placebo

Urinary Bladder, Neurogenic Clinical Trial using Fesoterodine 4 mg; Fesoterodine 8 mg; Oxybutynin; Fesoterodine

Pfizer - Recruiting 6 years to 16 years.
- A 12-Week Randomized, Open-Label, Active Comparator Period Followed By A 12-Week Safety Extension Period To Evaluate The Safety And Efficacy Of Fesoterodine In Subjects Aged 6 To 16 Years And >25 Kg With Symptoms Of Detrusor Overactivity Associated With A Neurological Condition (Neurogenic Detrusor Overactivity).
Fesoterodine 4 mg; Fesoterodine 8 mg; Oxybutynin; Fesoterodine

Cerebral Palsy, or Spasticity Clinical Trial using IncobotulinumtoxinA (8 Units per kg body weight); IncobotulinumtoxinA (6 Units per kg body weight); IncobotulinumtoxinA (2 Units per kg body weight)

Merz Pharmaceuticals GmbH - Recruiting 2 years to 17 years.
- Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeominr (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy.
IncobotulinumtoxinA (8 Units per kg body weight); IncobotulinumtoxinA (6 Units per kg body weight); IncobotulinumtoxinA (2 Units per kg body weight)

Major Depressive Disorder Clinical Trial using DVS SR

Pfizer - Recruiting 7 years to 18 years.
- A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (DVS SR) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder.
DVS SR

Influenza Virus Clinical Trial using Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV); Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)

Novartis - Recruiting 6 Months to 72 Months.
- A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ò6 to < 72 Months of Age..
Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV); Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)

Lower Limb Spasticity Due to Cerebral Palsy Clinical Trial using IncobotulinumtoxinA (16 Units per kg body weight); IncobotulinumtoxinA (12 Units per kg body weight); IncobotulinumtoxinA (4 Units per kg body weight)

Merz Pharmaceuticals GmbH - Recruiting 2 years to 17 years.
- Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeominr (incobotulinumtoxinA, NT 201) for the Treatment of Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy.
IncobotulinumtoxinA (16 Units per kg body weight); IncobotulinumtoxinA (12 Units per kg body weight); IncobotulinumtoxinA (4 Units per kg body weight)

Suicidal Ideation Clinical Trial using Group Intervention; Treatment as usual

Children's Hospital of Eastern Ontario - Recruiting 13 years to 17 years.
- Brief Group Intervention for Adolescents With Mild to Moderate Suicidal Ideation and Their Caregivers: Preliminary Investigation for a Novel Treatment Approach.
Group Intervention; Treatment as usual

Epilepsy, Partial Seizures Clinical Trial using Pregabalin add-on therapy

Pfizer - Recruiting 4 years to 16 years.
- A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Pregabalin As Adjunctive Therapy in Children 4 -16 Years of Age With Partial Onset Seizures.
Pregabalin add-on therapy

Epilepsy, Partial Seizures Clinical Trial using Pregabalin

Pfizer - Recruiting 1 Month to 65 years.
- A 12-Month Open-Label Study To Evaluate The Safety And Tolerability Of Pregabalin As Adjunctive Therapy In Children 1 Month To 16 Years Of Age With Partial Onset Seizures And Child And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures.
Pregabalin

Childhood Obesity Clinical Trial using Multidisciplinary, family-centered lifestyle intervention with behavioral counseling

Lawson Health Research Institute - Recruiting 2 years to 5 years.
- FOR HEALTH: A Family-ORiented Healthy Eating, Activity and Lifestyle Training With Hands-on Experience for Overweight and Obese Preschool Children and Their Families - a Pilot Trial..
Multidisciplinary, family-centered lifestyle intervention with behavioral counseling

Growth Hormone Disorder, or Growth Hormone Deficiency in Children Clinical Trial using NNC0195-0092; somatropin

Novo Nordisk - Recruiting 6 years to 13 years.
- A Randomised, Open-labelled, Active-controlled, Multinational, Dose-escalation Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (NNC0195-0092) Compared to Daily Dosing of Norditropinr SimpleXxr in Children With Growth Hormone Deficiency.
NNC0195-0092; somatropin

Systemic Infections Clinical Trial using CAZ-AVI

AstraZeneca - Recruiting 3 Months to 17 years.
- A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection.
CAZ-AVI

Lower Limb and Combined Lower Limb and Upper Limb Spasticity Due Clinical Trial using IncobotulinumtoxinA (16-20 Units per kg body weight)

Merz Pharmaceuticals GmbH - Recruiting 2 years to 17 years.
- Open-label, Non-controlled, Multicenter Long-term Study to Investigate the Safety and Efficacy of Xeominr (Incobotulinumtoxin A, NT 201) for the Treatment of Spasticity of the Lower Limb(s) or of Combined Spasticity of Upper and Lower Limb in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy.
IncobotulinumtoxinA (16-20 Units per kg body weight)

Phenylketonuria, or Mild Hyperphenylalaninemia Clinical Trial

The Hospital for Sick Children - Recruiting 18 years or older.
- Neuropsychological and Quality of Life Outcomes in Untreated Adults With Mild Hyperphenylalaninemia With Phenylalanine Levels Between 360 and 600 æmol/L..

Congenital Heart Defects Clinical Trial

New England Research Institutes - Recruiting N/A or older.
- Congenital Heart Disease GEnetic NEtwork Study (CHD GENES).

Acquired Immune Deficiency Syndrome (AIDS), or HIV Infections Clinical Trial using E/C/F/TAF

Gilead Sciences - Recruiting 12 years to 17 years.
- A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents.
E/C/F/TAF

Generalized Tonic Clonic Seizures Clinical Trial using Pregabalin Dose Level 1; Pregabalin Dose Level 2; Placebo

Pfizer - Recruiting 5 years to 65 years.
- A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial of Pregabalin As Adjunctive Therapy in Pediatric and Adult Subjects With Primary Generalized Tonic Clonic Seizures - Protocol A0081105.
Pregabalin Dose Level 1; Pregabalin Dose Level 2; Placebo

Cystic Fibrosis Clinical Trial

National Jewish Health - Recruiting 7 years to 82 years.
- Cystic Fibrosis Nontuberculous Mycobacteria Diagnosis Protocol.

Hepatitis B, Chronic Clinical Trial using peginterferon alfa-2a [Pegasys]

Hoffmann-La Roche - Recruiting 3 years to 17 years.
- A Phase IIIb Parallel Group, Open Label Study of Pegylated Interferon Alfa-2a Monotherapy (PEG-IFN, Ro 25-8310) Compared to Untreated Control in Children With HBeAg Positive Chronic Hepatitis B.
peginterferon alfa-2a [Pegasys]

Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Ne Clinical Trial using questionnaire administration; cognitive assessment; psychosocial assessment and care; quality-of-life assessment

Children's Oncology Group - Recruiting 1 Month to 21 years.
- Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer.
questionnaire administration; cognitive assessment; psychosocial assessment and care; quality-of-life assessment

Narcolepsy Clinical Trial using Armodafinil

Teva Pharmaceutical Industries - Recruiting 6 years to 17 years.
- A Randomized, Open-Label Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Single and Multiple Doses of Armodafinil (50, 100, and 150 mg/Day) in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy.
Armodafinil

Acute Myeloid Leukemia Clinical Trial using Phase1 and Phase 2: decitabine; Phase 1: cytarabine; Phase 2: cytarabine

Janssen Research & Development, LLC - Recruiting 1 Month to 18 years.
- Phase 1-2 Safety and Efficacy Study of DACOGEN in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia.
Phase1 and Phase 2: decitabine; Phase 1: cytarabine; Phase 2: cytarabine

Autism Spectrum Disorder Clinical Trial

St. Louis University - Recruiting 6 Months to 36 Months.
- Early Detection of Autism Spectrum Disorder in Children.

Autism Spectrum Disorders Clinical Trial using Provider Education Model (PEM)

Hugo W. Moser Research Institute at Kennedy Krieger, Inc. - Recruiting 24 Months to 42 Months.
- Improving Part C Services and Outcomes for Under-resourced Children With ASD.
Provider Education Model (PEM)

Hypertension, or Chronic Kidney Disease Clinical Trial using Valsartan

Novartis - Recruiting 6 years to 17 years.
- A Multicenter, Open-label, 18 Month Study to Evaluate the Long-term Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age With Hypertension and With or Without Chronic Kidney Disease.
Valsartan

Celiac Disease, or Eosinophilic Esophagitis Clinical Trial

Tampere University Hospital - Recruiting N/A to 17 years.
- Improved Diagnostics of Celiac Disease in Children.

Childhood Asthma, or Allergy Clinical Trial using Ventilation; Placebo Ventilation

University of Aarhus - Recruiting 5 years to 18 years.
- AsthmaVent - Effect of Mechanical Ventilation on Asthma Control in Children.
Ventilation; Placebo Ventilation

Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peri Clinical Trial using pegylated liposomal doxorubicin (PLD); VTX-2337; Placebo

VentiRx Pharmaceuticals Inc. - Recruiting 18 years or older.
- A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
pegylated liposomal doxorubicin (PLD); VTX-2337; Placebo

Obesity, Obesity, Morbid, Pregnancy, Complications; Cesarean Sect Clinical Trial using Enoxaparin

MemorialCare Health System - Recruiting 18 years or older.
- Comparing Anti-XA Levels in Post-Cesarean Patients With BMI >35 Undergoing Enoxaparin Thromboprophylaxis With Weight Based Dosing Twice Daily Versus Fixed Dose 40 Milligrams Daily.
Enoxaparin

Sickle Cell Disease Clinical Trial using NiCord

Gamida Cell ltd - Recruiting 2 years to 21 years.
- Allogeneic Stem Cell Transplantation of NiCordr, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Combination With a Second, Unmanipulated Cord Blood Unit in Patients With Sickle Cell Disease.
NiCord

B-cell Childhood Acute Lymphoblastic Leukemia, Cognitive/Function Clinical Trial using cognitive assessment; psychosocial assessment and care; diffusion tensor imaging; laboratory biomarker analysis; pharmacological study

Children's Oncology Group - Recruiting 1 year to 17 years.
- A Study of Neurocognitive Function in Children Treated for ALL.
cognitive assessment; psychosocial assessment and care; diffusion tensor imaging; laboratory biomarker analysis; pharmacological study

Cystic Fibrosis Clinical Trial using Aztreonam for Inhalation Solution (AZLI); Placebo

Gilead Sciences - Recruiting 6 years or older.
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy (CAT) Regimen of Inhaled Antibiotics for the Treatment of Chronic Pulmonary Pseudomonas Aeruginosa Infection in Subjects With Cystic Fibrosis.
Aztreonam for Inhalation Solution (AZLI); Placebo

Lymphoma, or Nonneoplastic Condition Clinical Trial using bleomycin sulfate; filgrastim; ABVD regimen; BEACOPP regimen; cyclophosphamide; dacarbazine; doxorubicin hydrochloride; etoposide; prednisone; procarbazine hydrochloride; vinblastine sulfate; vincristine sulfate

Southwest Oncology Group - Recruiting 18 years to 60 years.
- A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging.
bleomycin sulfate; filgrastim; ABVD regimen; BEACOPP regimen; cyclophosphamide; dacarbazine; doxorubicin hydrochloride; etoposide; prednisone; procarbazine hydrochloride; vinblastine sulfate; vincristine sulfate

Anal Cancer, Nonneoplastic Condition, Penile Cancer, or Precancer Clinical Trial using quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; laboratory biomarker analysis

AIDS Malignancy Clinical Trials Consortium - Recruiting 13 years to 26 years.
- AMC-072: Protective Effect of Quadrivalent Vaccine in Young HIV-Positive Males Who Have Sex With Males.
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; laboratory biomarker analysis

Kidney Cancer Clinical Trial using everolimus; placebo

Southwest Oncology Group - Recruiting 18 years or older.
- EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study.
everolimus; placebo

Neurofibromatosis Type 1, or Plexiform Neurofibroma Clinical Trial using PEG-interferon alfa-2b

National Institutes of Health Clinical Center (CC) - Recruiting 6 Months to 21 years.
- A Phase II Trial of Peginterferon Alpha-2b (PEG-Intron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform Neurofibromas.
PEG-interferon alfa-2b

Malaria Clinical Trial using Oral Activated Charcoal

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 10 years.
- Effect of Oral Activated Charcoal on Parasite Clearance Rates in Response to Intravenous Artesunate in Malian Children With Uncomplicated Plasmodium Falciparum Malaria.
Oral Activated Charcoal

Multiple Endocrine Neoplasia Type 2A, or Multiple Endocrine Neopl Clinical Trial using ZACTIMA (Vandetanib)

National Institutes of Health Clinical Center (CC) - Recruiting 5 years to 18 years.
- Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Carcinoma.
ZACTIMA (Vandetanib)

Bronchiolitis Obliterans, Chronic Graft Versus Host Disease, Leuk Clinical Trial using Montelukast sodium; Flow cytometry; Laboratory biomarker analysis; Quality-of-life assessment

National Institutes of Health Clinical Center (CC) - Recruiting 6 years to 80 years.
- Multi-Institutional Prospective Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic or Autologous Stem Cell Transplantation in Children and Adults.
Montelukast sodium; Flow cytometry; Laboratory biomarker analysis; Quality-of-life assessment

Developmental Delay Disorders, Chromosome Deletion, Mental Retard Clinical Trial using dTR Melatonin (NIH CC PDS); Phototherapy (Bright Light); Melatonin CR

National Institutes of Health Clinical Center (CC) - Recruiting 5 years to 45 years.
- A Phase One Treatment Trial of the Circadian Sleep Disturbance in Smith-Magenis Syndrome (SMS).
dTR Melatonin (NIH CC PDS); Phototherapy (Bright Light); Melatonin CR

X-linked Severe Combined Immunodeficiency, XSCID, SCID-X1, or Gam Clinical Trial using Gene Transfer

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 30 years.
- Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency.
Gene Transfer

Attention Deficit Disorder With Hyperactivity, Attention Deficit Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 4 years to 8 years.
- Near Infra-Red Spectroscopy (NIRS) in Neurodevelopmental Disorders and Typically Developing Children.

Genetic Disorder, or Metabolic Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A to 18 years.
- Studies of Pediatric Patients With Metabolic or Other Genetic Disorders.

Cerebral Palsy, Children, or Adolescents Clinical Trial using Physical Exercise

National Institutes of Health Clinical Center (CC) - Recruiting 5 years to 17 years.
- Physical, Functional and Neurological Effects of Two Lower Extremity Exercise Programs in Children With Cerebral Palsy.
Physical Exercise

Solid Tumor, Leukemia, or Neurofibromatosis Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 6 years or older.
- Validation of the English Version of the Pain Interference Index and the Pain Rating Scale in Children, Adolescents, and Young Adults With Chronic Illness and Their Parents.

Cerebral Palsy Clinical Trial using Sativex; Placebo

GW Pharmaceuticals Ltd. - Recruiting 8 years to 18 years.
- The Efficacy, Safety and Tolerability of Sativex as an Adjunctive Treatment to Existing Anti-spasticity Medications in Children Aged 8 to 18 Years With Spasticity Due to Cerebral Palsy or Traumatic Central Nervous System Injury Who Have Not Responded Adequately to Their Existing Anti-spasticity Medications: a Parallel Group Randomised, Double-blind, Placebo-controlled Study Followed by a 24-week Open Label Extension Phase.
Sativex; Placebo

Solid Tumors, Brain Tumors, Sarcoma, Wilm's Tumor, or Rhabdomyosa Clinical Trial using NK cellular therapy; rhIL-15

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 29 years.
- A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults With Refractory Solid Tumors.
NK cellular therapy; rhIL-15

Community Acquired Pneumonia Clinical Trial using BPS; Guideline

Hospital General de Ni¤os Pedro de Elizalde - Recruiting 3 Months to 5 years.
- Efficacy of BPS (Bacterial Pneumonia Score) Guided Antibiotic Use in Children With Community Acquired Pneumonia on Reducing Antibiotic Use as Compared to Standard Care Practice (Current Guidelines for CAP) in the Era of Pneumococcal Vaccine.
BPS; Guideline

Anemia, Sickle Cell Clinical Trial using systematic psychological care

Fondation Ophtalmologique Adolphe de Rothschild - Recruiting N/A to 18 years.
- The Impact of Systematic Psychological and Medical Care for Treatment of Pediatric Patients With SCD: : A Luxury or a Necessity?.
systematic psychological care

Ewing's Sarcoma, Leukemia, Lymphoma, Neoplasm, or Sarcoma Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 3 Months to 40 years.
- Treatment of Children With Cancer.

GIST Clinical Trial using Vandetanib

National Institutes of Health Clinical Center (CC) - Recruiting 3 years or older.
- Phase II Trial of Vandetanib (ZD6474, ZACTIMA (TM)) in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors.
Vandetanib

Non Hodgkin's Lymphoma Clinical Trial using filgrastim; Rituximab

National Institutes of Health Clinical Center (CC) - Recruiting 12 years or older.
- Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children With Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma.
filgrastim; Rituximab

Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Stage I Clinical Trial using laboratory biomarker analysis

Children's Oncology Group - Recruiting N/A or older.
- Categorization of Wilms Tumors by Genetic Expression.
laboratory biomarker analysis

Cancer Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 65 years.
- Characterizing Lone Parenting: A Multi-Institutional Pilot Study of the Perceptions of Support and Perceived Stress of Lone Parents of Children With Cancer.

All Malignancies, or Children Being Treated for Catastrophic Illn Clinical Trial using Blood draw

St. Jude Children's Research Hospital - Recruiting N/A or older.
- Pharmacogenetic Determinants Of Treatment Response In Children.
Blood draw

Minors, Obesity, Substance Abuse, Violence, or Mental Health Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 13 years to 22 years.
- Health Behavior in School-Age Children: NEXT Longitudinal Study 2009-2013.

Pediatric Cancer, Leukemia, Sarcoma, or Brain Tumors Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A to 18 years.
- Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN) Children s Oncology Group.

Childhood Acute Lymphoblastic Leukemia Clinical Trial using PEG-L-asparaginase ind; PEG-L-asparaginase cons; E.coli L-asparaginase; High-dose Methotrexate; Low-dose Methotrexate; Triple intrathecal therapy; Cranial irradiation; Daunorubicin

Federal Research Institute of Pediatric Hematology, Oncology and Immunology - Recruiting 1 year to 18 years.
- Moscow-Berlin 2008 Multicenter Randomised Study for Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents.
PEG-L-asparaginase ind; PEG-L-asparaginase cons; E.coli L-asparaginase; High-dose Methotrexate; Low-dose Methotrexate; Triple intrathecal therapy; Cranial irradiation; Daunorubicin

Whooping Cough Clinical Trial using Full price; $5 off

Children's Hospital of Philadelphia - Recruiting 18 years or older.
- Retail Pharmacy Vouchers to Promote Tdap Vaccination for Adults Living With Infants.
Full price; $5 off

Children, or Adolescents Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 10 years to 21 years.
- Validation of the Ask Suicide-Screening Questions (ASQ) in the Inpatient Medical Setting.

HIV Infection, or Neoplasm Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 7 years to 17 years.
- Psychological Benefits of a Normalized Camping Experience for Children With Cancer.

Autoimmune Disease, Congenital Adrenal Hyperplasia, Healthy, Ment Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 3 years or older.
- Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Controls.

Neurofibromatosis Type 1, Malignant Peripheral Nerve Sheath Tumor Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults With Neurofibromatosis Type 1.

Williams Syndrome Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 5 years to 55 years.
- Defining the Brain Phenotype of Children With Williams Syndrome.

Undiagnosed Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- The Role of Uncertainty in Coping Efficacy: The Experience of Parents of Children With Undiagnosed Medical Conditions.

Asthma, Diabetes, Obesity, Premature Birth, or Autistic Disorder Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Vanguard Phase of the National Children s Study.

Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, or High Clinical Trial using Lenalidomide; Radiation Therapy

National Institutes of Health Clinical Center (CC) - Recruiting 1 year to 21 years.
- A Phase I Trial of Lenalidomide and Radiotherapy in Children With Diffuse Intrinsic Pontine Gliomas and High-grade Gliomas.
Lenalidomide; Radiation Therapy

Parents of Children With Cancer Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Understanding the Perceived Influence of Childhood Cancer on the Parents' Marital/Partner Relationship: A Descriptive Study.

Autism Spectrum Disorders Clinical Trial using Donepezil; Placebo

National Institutes of Health Clinical Center (CC) - Recruiting 24 Months to 50 Months.
- A Randomized Controlled Trial of Donepezil for REM Enhancement and Behavioral Change in Autism.
Donepezil; Placebo

HIV, or Disclosure Clinical Trial using Amagugu Counseling Intervention

University of KwaZulu - Recruiting 16 years or older.
- Maternal HIV Disclosure to School Children: RCT of Family-based Intervention (Amagugu).
Amagugu Counseling Intervention

Neuromuscular Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Development of a Proxy Motor Outcome Measure in Young Children With Neuromuscular Disease.

Inborn Genetic Diseases, or Pentalogy of Cantrell Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Mutations in Genes Associated With Pentalogy of Cantrell or Non-Muscle Myosin II Syndromes.

Maternal Fetal Factors Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Biological Markers of Disease in the Prediction of Preterm Delivery, Preeclampsia and Intra-Uterine Growth Restriction: A Longitudinal Study.

Diabetes, Cancer, or Cardiovascular Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Development of the Family Map: Examination of Communal Coping Across Disease Context.

Neuroblastoma;, Rhabdomyosarcoma;, Ewing's Sarcoma;, Ewing's Tumo Clinical Trial using nab-paclitaxel

Celgene Corporation - Recruiting 6 Months to 21 years.
- A Phase 1 / 2, Multicenter, Open-label, Dose-finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors.
nab-paclitaxel

Askin Tumor, Localized Ewing Sarcoma/Peripheral Primitive Neuroec Clinical Trial using laboratory biomarker analysis

Children's Oncology Group - Recruiting N/A to 21 years.
- A COG Study for Collecting and Banking Ewing Sarcoma Specimens.
laboratory biomarker analysis

Diffuse Large Cell Lymphoma, Burkitt's Lymphoma, or High Grade B- Clinical Trial using Rituximab; IT Cytarabine

New York Medical College - Recruiting 3 years to 31 years.
- Reduced Burden of Oncologic Therapy in Advanced B-cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults With CD20+ Mature B-Cell Lymphoma.
Rituximab; IT Cytarabine

Urinary Incontinence Clinical Trial using Surgery; Medical Treatment

University of British Columbia - Recruiting 5 years to 18 years.
- Treatment of Persistent Urinary Incontinence in Children.
Surgery; Medical Treatment

Disseminated Neuroblastoma, Localized Resectable Neuroblastoma, L Clinical Trial using laboratory biomarker analysis; polymerase chain reaction; polyacrylamide gel electrophoresis; DNA analysis

Children's Oncology Group - Recruiting N/A or older.
- Analysis of Circulating MYCN DNA in Serum Samples Obtained From Patients With Neuroblastoma.
laboratory biomarker analysis; polymerase chain reaction; polyacrylamide gel electrophoresis; DNA analysis

Central Nervous System Malignancies, or Ependymoma Clinical Trial using 5-fluorouracil

St. Jude Children's Research Hospital - Recruiting 1 Month to 21 years.
- Phase I Study of 5-Fluorouracil in Children and Young Adults With Recurrent Ependymoma.
5-fluorouracil

Respiratory Failure Clinical Trial using Neurally Adjusted Ventilatory Assist (NAVA)

Children's Hospital Boston - Recruiting 1 Month to 18 years.
- Regional Distribution Differences Between Neurally Adjusted Ventilatory Assist and Pressure Support Ventilation.
Neurally Adjusted Ventilatory Assist (NAVA)

Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor, Hepatic T Clinical Trial using alemtuzumab; fludarabine; sirolimus; Busulfan; melphalan; stem cells

St. Jude Children's Research Hospital - Recruiting 2 years to 21 years.
- A Phase I Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas.
alemtuzumab; fludarabine; sirolimus; Busulfan; melphalan; stem cells

Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphob Clinical Trial using Clofarabine; Mitoxantrone

New York Medical College - Recruiting N/A to 30 years.
- A Pilot Study of Mitoxantrone in Combination With Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) With Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin Lymphoma.
Clofarabine; Mitoxantrone

Untreated Childhood Medulloblastoma Clinical Trial using vincristine sulfate; cyclophosphamide; methotrexate; etoposide; carboplatin; laboratory biomarker analysis; cognitive assessment

Children's Oncology Group - Recruiting N/A to 47 Months.
- A Phase II Study For The Treatment Of Non-Metastatic Nodular Desmoplastic Medulloblastoma In Children Less Than 4 Years Of Age.
vincristine sulfate; cyclophosphamide; methotrexate; etoposide; carboplatin; laboratory biomarker analysis; cognitive assessment

Acquired Immune Deficiency Syndrome (AIDS), or HIV Infections Clinical Trial using Elvitegravir; RTV-boosted PI

Gilead Sciences - Recruiting N/A to 17 years.
- A Phase 2/3 Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG)Administered With a Background-Regimen (BR) Containing a Ritonavir-Boosted Protease Inhibitor (PI/r) in HIV-1 Infected, Antiretroviral Treatment-Experienced Pediatric Subjects.
Elvitegravir; RTV-boosted PI

Prediction of Extubation Readiness Clinical Trial using Cardiorespiratory signal acquisition

McGill University Health Center - Recruiting N/A or older.
- Prediction of Extubation Readiness in Extreme Preterm Infants by the Automated Analysis of CardioRespiratory Behavior: the APEX Study.
Cardiorespiratory signal acquisition

Advanced Rare Tumours Clinical Trial using Sunitinib; Temsirolimus

NCIC Clinical Trials Group - Recruiting 16 years or older.
- A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours.
Sunitinib; Temsirolimus

Hemophilia A Clinical Trial using BAY94-9027

Bayer - Recruiting N/A to 12 years.
- A Multi-center, Phase III, Non-controlled, Open-label Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of BAY94-9027 for Prophylaxis and Treatment of Bleeding in Previously Treated Children (Age <12 Years) With Severe Hemophilia A.
BAY94-9027

Influenza Clinical Trial using oseltamivir [Tamiflu]

Hoffmann-La Roche - Recruiting N/A to 12 years.
- AN OPEN-LABEL, RANDOMIZED, ADAPTIVE, TWO-ARM, MULTICENTER TRIAL TO EVALUATE PHARMACOKINETICS AND PHARMACODYNAMICS OF TWO DOSES OF OSELTAMIVIR (TAMIFLUr) IN THE TREATMENT OF INFLUENZA IN IMMUNOCOMPROMISED CHILDREN, FROM 2 WEEKS TO LESS THAN 13 YEARS OF AGE, WITH CONFIRMED INFLUENZA INFECTION.
oseltamivir [Tamiflu]

Diabetes, or Diabetes Mellitus, Type 1 Clinical Trial using insulin degludec/insulin aspart; insulin aspart; insulin detemir

Novo Nordisk - Recruiting 1 year to 17 years.
- A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus.
insulin degludec/insulin aspart; insulin aspart; insulin detemir

Neuroblastoma Clinical Trial using laboratory biomarker analysis; cytology specimen collection procedure; questionnaire administration

Children's Oncology Group - Recruiting N/A or older.
- Genetic Susceptibility Factors in the Etiology of Neuroblastoma Also Known as Neuroblastoma Epidemiology in North America (NENA).
laboratory biomarker analysis; cytology specimen collection procedure; questionnaire administration

B-cell Childhood Acute Lymphoblastic Leukemia, Philadelphia Chrom Clinical Trial using doxorubicin hydrochloride; cytarabine; vincristine sulfate; dexamethasone; pegaspargase; methotrexate; mercaptopurine tablet; leucovorin calcium; cyclophosphamide; thioguanine; quality-of-life assessment; questionnaire administration; laboratory biomarker analysis

Children's Oncology Group - Recruiting 1 year to 30 years.
- Treatment of Patients With Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL).
doxorubicin hydrochloride; cytarabine; vincristine sulfate; dexamethasone; pegaspargase; methotrexate; mercaptopurine tablet; leucovorin calcium; cyclophosphamide; thioguanine; quality-of-life assessment; questionnaire administration; laboratory biomarker analysis

Myopia Clinical Trial using massager

Korean Medicine Hospital of Pusan National University - Recruiting 7 years to 12 years.
- An Integrative Medical Approach of Acupoint Stimulation for Children With Myopia : A Pilot Study.
massager

Malignant Neoplasm Clinical Trial using music therapy; caregiver-related intervention or procedure; questionnaire administration; quality-of-life assessment

Children's Oncology Group - Recruiting 11 years to 24 years.
- Music Video for AYA-Parent Communication and Resilience.
music therapy; caregiver-related intervention or procedure; questionnaire administration; quality-of-life assessment

Leukemia Clinical Trial using compliance monitoring; telephone-based intervention; mercaptopurine; computer-assisted intervention; counseling intervention; questionnaire administration; study of socioeconomic and demographic variables; standard follow-up care

Children's Oncology Group - Recruiting 6 Months to 25 years.
- A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL.
compliance monitoring; telephone-based intervention; mercaptopurine; computer-assisted intervention; counseling intervention; questionnaire administration; study of socioeconomic and demographic variables; standard follow-up care

Suspected CSF Shunt Obstruction Clinical Trial using ShuntCheck-Micro-Pumper (SCMP); Imaging

NeuroDx Development - Recruiting 35 Months to 20 years.
- An Operator-Blinded Study of the Efficacy of ShuntCheck-Micro-Pumper, a Non-Invasive Diagnostic Procedure, in Detecting Ventricular Shunt Patency or Occlusion and in Predicting Clinical Outcome in Children and Adolescents Presenting to Emergency Departments and Neurosurgery Clinics.
ShuntCheck-Micro-Pumper (SCMP); Imaging

Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET) Clinical Trial using laboratory biomarker analysis; questionnaire administration

Children's Oncology Group - Recruiting N/A or older.
- Genetic Epidemiology of Ewing's Sarcoma.
laboratory biomarker analysis; questionnaire administration

Hodgkin's Disease, Non-Hodgkin's Lymphoma, Lymphoproliferative Di Clinical Trial using LMP, BARF1 & EBNA1 specific CTLs: A; LMP, BARF1 & EBNA1 specific CTLs : B

Baylor College of Medicine - Recruiting N/A or older.
- Administration of Rapidly Generated LMP, BARF1 And EBNA1 Specific Cytotoxic T-Lymphocytes To Patients With EBV-Positive Lymphoma.
LMP, BARF1 & EBNA1 specific CTLs: A; LMP, BARF1 & EBNA1 specific CTLs : B

CSF Flow Through the Shunt of a Hydrocephalus Patient Clinical Trial using ShuntCheck

NeuroDx Development - Recruiting N/A to 85 years.
- Physician Preference Study of the Utility of ShuntCheck to Detect Cerebrospinal Fluid (CSF) in Patients With Ventriculo-Peritoneal CSF Shunts.
ShuntCheck

Hodgkin Lymphoma, Non-Hodgkin Lymphoma, or Hodgkin Disease Clinical Trial using Antigen Escalation Stage; Dose escalation study of T cells

Baylor College of Medicine - Recruiting N/A or older.
- Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients With Active or Relapsed Hodgkin or Non-Hodgkin Lymphoma.
Antigen Escalation Stage; Dose escalation study of T cells

Cystic Fibrosis Clinical Trial

University Hospitals of Cleveland - Recruiting 18 years to 50 years.
- The Role of IL-17 Neutrophils in CF Lung Inflammation.

Graft vs Host Disease Clinical Trial

University of British Columbia - Recruiting N/A to 18 years.
- Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team) - Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease.

Rubella, Measles, or Mumps Clinical Trial using GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762).; Merck & Co., Inc.'s M-M-RrII (also called M-M-R Vax Pror), combined measles-mumps-rubella virus vaccine.; Varivaxr (Merck & Co., Inc.); Havrixr; Prevnar 13r (Pfizer Inc.)

GlaxoSmithKline - Recruiting 12 Months to 15 Months.
- Consistency Study of GSK Biologicals' MMR Vaccine (209762) (Priorixr) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M RrII), in Healthy Children 12 to 15 Months of Age.
GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762).; Merck & Co., Inc.'s M-M-RrII (also called M-M-R Vax Pror), combined measles-mumps-rubella virus vaccine.; Varivaxr (Merck & Co., Inc.); Havrixr; Prevnar 13r (Pfizer Inc.)

Arthritis, Juvenile Rheumatoid Clinical Trial using Sulfasalazine

Pfizer - Recruiting 6 years to 17 years.
- An Open Label Non-Randomized Study To Characterize The Steady State Pharmacokinetics Of Sulfasalazine Delayed Release Tablets In Children With Juvenile Idiopathic Arthritis.
Sulfasalazine

Hepatitis A Clinical Trial using Influenza vaccine GSK2321138A; Havrix Junior; Wyeth Prevenar; Sanofi Pasteur Varivax/ProVarivax; Varilrix

GlaxoSmithKline - Recruiting 6 Months to 35 Months.
- An Efficacy Study of GSK Biologicals' Quadrivalent Influenza Vaccine GSK2321138A (FLU D-QIV) When Administered in Children.
Influenza vaccine GSK2321138A; Havrix Junior; Wyeth Prevenar; Sanofi Pasteur Varivax/ProVarivax; Varilrix

Asthma Clinical Trial using ADVAIR 100/50mcg; ADVAIR 250/50mcg; FLOVENT 100mcg; FLOVENT 250mcg

GlaxoSmithKline - Recruiting 4 years to 11 years.
- A 6-month Safety and Benefit Study of Inhaled Fluticasone Propionate/ Salmeterol Combination Versus Inhaled Fluticasone Propionate in the Treatment of 6,200 Pediatric Subjects 4-11 Years Old With Persistent Asthma.
ADVAIR 100/50mcg; ADVAIR 250/50mcg; FLOVENT 100mcg; FLOVENT 250mcg

Infections, Papillomavirus Clinical Trial using Cervarix; MMR; DTPa

GlaxoSmithKline - Recruiting 4 years to 25 years.
- Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old.
Cervarix; MMR; DTPa

Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemi Clinical Trial using cytology specimen collection procedure

Children's Oncology Group - Recruiting N/A to 30 years.
- A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors.
cytology specimen collection procedure

Spinal Cord Injuries Clinical Trial

Shriners Hospitals for Children - Recruiting 18 years or older.
- Long-term Outcomes and Life Satisfaction of Adults With Pediatric-Onset Spinal Cord Injuries.

Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Clinical Trial using laboratory biomarker analysis

Children's Oncology Group - Recruiting N/A to 21 years.
- Target: Identification for High Risk Childhood AML Based on Genome-Wide Analysis.
laboratory biomarker analysis

Hypoxic Ischemic Encephalopathy Clinical Trial

University Children's Hospital, Zurich - Recruiting N/A to 2 Weeks.
- Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS) Biomarkers of Neonatal Hypoxic Ischemic Encephalopathy.

Desmoid Tumor Clinical Trial using Sirolimus

Maine Medical Center - Recruiting N/A to 29 years.
- A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis.
Sirolimus

Spinal Cord Injury Clinical Trial

Shriners Hospitals for Children - Recruiting N/A to 18 years.
- Cardiovascular Measurements at Baseline and During Cystometry in Pediatric Spinal Cord Injury.

Sedation Clinical Trial using Propofol; Ketamine-Propofol

University Children's Hospital, Zurich - Recruiting 3 Months to 10 years.
- Untersuchung Unterschiedlicher Sedationstechniken fr Elektive Magnetresonanztomographie (MRT)-Diagnostik Bei Kindern Anhand Klinischer Und MRT-basierter Outcomeparameter (Propofol Versus Propofol-Ketamin).
Propofol; Ketamine-Propofol

Measles, Mumps, or Rubella Clinical Trial using GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762).; Merck & Co., Inc.'s M-M-RrII, combined measles-mumps-rubella virus vaccine live.; Varivaxr (Merck & Co., Inc.); Havrixr; Prevnar 13r (Pfizer Inc.)

GlaxoSmithKline - Recruiting 12 Months to 15 Months.
- Immunogenicity and Safety Study of GSK Biologicals' Priorixr Vaccine (209762) at an End of Shelf-life Potency Compared to Merck & Co., Inc.'s MMR Vaccine When Both Are Given on a 2-dose Schedule to Healthy Children in Their 2nd Year of Life.
GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762).; Merck & Co., Inc.'s M-M-RrII, combined measles-mumps-rubella virus vaccine live.; Varivaxr (Merck & Co., Inc.); Havrixr; Prevnar 13r (Pfizer Inc.)

Obesity Clinical Trial using metformin; Conjugated Linoleic Acid; Placebo; Healthy habits program

Laboratorios Silanes S.A. de C.V. - Recruiting 8 years to 18 years.
- Effect of an Intervention Program With Healthy Habits Plus Metformin or Conjugated Linoleic Acid Over Clinical Parameters and Molecular Pathways of Insulin Resistance in Obese Pediatric Patients.
metformin; Conjugated Linoleic Acid; Placebo; Healthy habits program

Rett Syndrome Clinical Trial using NNZ-2566; Placebo

Neuren Pharmaceuticals Limited - Recruiting 16 years to 45 years.
- A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study of NNZ-2566 in Rett Syndrome.
NNZ-2566; Placebo

Hunter Syndrome Clinical Trial using idursulfase-IT; No IT treatment

Shire Human Genetic Therapies, Inc. - Recruiting N/A to 18 years.
- A Controlled, Randomized, Two-arm, Open-label, Assessor-blinded, Multicenter Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elapraser in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment.
idursulfase-IT; No IT treatment

Spinal Muscular Atrophy Clinical Trial using ISIS-SMNRx

Isis Pharmaceuticals - Recruiting 2 years to 15 years.
- An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy.
ISIS-SMNRx

Shigella Infection Clinical Trial using Placebo; WRSs2; WRSs3

National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting 18 years to 45 years.
- Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3.
Placebo; WRSs2; WRSs3

Adult Rhabdomyosarcoma, Childhood Desmoplastic Small Round Cell T Clinical Trial using biologic sample preservation procedure; laboratory biomarker analysis

Children's Oncology Group - Recruiting N/A to 50 years.
- A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol.
biologic sample preservation procedure; laboratory biomarker analysis

Ewing Sarcoma, or Sarcoma Clinical Trial using Mithramycin

National Institutes of Health Clinical Center (CC) - Recruiting 1 year or older.
- Phase I/II Trial of Mithramycin in Children and Adults With Refractory Extracranial Solid Tumors (Phase I) or Ewing Sarcoma and EWSFLI1 Fusion Transcript (Phase II).
Mithramycin

Asthma Clinical Trial using Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg; Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg; Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg; Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg; Placebo Metered Dose Inhaler (MDI); Placebo Dry Powder Inhaler (DPI)

Merck Sharp & Dohme Corp. - Recruiting 5 years to 11 years.
- A 12-Week, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Mometasone Furoate Metered Dose Inhaler in the Treatment of Children Ages 5 to 11 Years With Persistent Asthma.
Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg; Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg; Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg; Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg; Placebo Metered Dose Inhaler (MDI); Placebo Dry Powder Inhaler (DPI)

Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Ac Clinical Trial using supersaturated calcium phosphate rinse; placebo; questionnaire administration; quality-of-life assessment

Children's Oncology Group - Recruiting 4 years to 21 years.
- A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation.
supersaturated calcium phosphate rinse; placebo; questionnaire administration; quality-of-life assessment

Disseminated Neuroblastoma, Localized Resectable Neuroblastoma, L Clinical Trial using laboratory biomarker analysis; cytology specimen collection procedure

Children's Oncology Group - Recruiting N/A to 30 years.
- Neuroblastoma Biology Studies.
laboratory biomarker analysis; cytology specimen collection procedure